In children with transfusion-dependent thalassemia, inflammation and neuronal damage biomarkers are associated with affective and chronic fatigue symptoms.

Maha Abdul Saheb Ridhaa ^a, Hussein Kadhem Al-Hakeim ^b, Mohammed K. Kahlol ^c, Tabarek Hadi Al-Naqeeb ^d, Michael Maes ^{e, f, g, h, i *}

headm2010@yahoo.com

- ^c Department of Chemistry, College of Science, University of Kufa, Iraq. E-mail: mohkhayoun@gmail.com
- d Medical Laboratory Technology Department, College of Medical Technology, The Islamic University, Najaf, Iraq. E-mail: tbarkalnqvb853@gmail.com.

*Correspondence Author: Prof.Dr. Michael Maes, Sichuan Provincial Center for Mental Health, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu 610072, China. Email: dr.michaelmaes@hotmail.com. https://scholar.google.co.th/citations?user=1wzMZ7UAAAAJ&hl=th&oi=ao

^a Department of Chemistry, Faculty of Science, University of Kufa, Iraq. E-mail: mahaa.muhammad@uokufa.edu.iq

^b Department of Chemistry, College of Science, University of Kufa, Iraq. E-mail:

^e Department of Psychiatry, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.

f Department of Psychiatry, Medical University of Plovdiv, Plovdiv, Bulgaria

^g Sichuan Provincial Center for Mental Health, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu 610072, China

^h Key Laboratory of Psychosomatic Medicine, Chinese Academy of Medical Sciences, Chengdu, 610072, China

ⁱ Kyung Hee University, Seoul, Dongdaemun-gu, South Korea.

Abstract

Background. Patients with transfusion-dependent thalassemia (TDT) are vulnerable to neurotoxicity due to frequent blood transfusions and the subsequent iron overload (IO) and inflammation. As a result, affective (depression and anxiety) and chronic fatigue syndrome (CFS) symptoms may develop.

Aims: To investigate the potential association between TDT and neuronal injury, as assessed with serum concentrations of neuronal damage biomarkers, including neurofilament light (NFL), glial fibrillary acidic protein (GFAP), neuron-specific enolase (NSE), and nestin.

Methods: We investigated the associations between those CNS injury biomarkers, neuro-immune markers (C-reactive protein (CRP), interleukin (IL)-6, and IL-10), calcium, magnesium, copper and zinc, and the Fibro-Fatigue (FF), the Children's Depression Inventory (CDI), and the Spence Children's Anxiety Scale (SCAS) scores in 126 children with TDT and 41 healthy children.

Results. TDT children show significant increases in IO, FF, CDI, and SCAS scores, serum NSE, GFAP, NF-L, CRP, copper, IL-6, and IL-10, and lowered magnesium, zinc, and calcium as compared with healthy children. There were significant correlations between the CDI score and NFL, NSE and GFAP; SCAS score and NFL, and FF score and NFL and GFAP. The neuronal damage biomarkers (except nestin) were significantly associated with inflammatory, erythron (hematocrit and hemoglobin) and IO (iron and ferritin) biomarkers.

Conclusions. TDT is characterized by intertwined increases in neuronal injury biomarkers and neuropsychiatric symptoms suggesting that TDT-associated neurotoxicity plays a role in affective symptoms and CFS due to TDT. Inflammation and neurotoxicity are novel drug targets for the prevention of affective symptoms and CFS due to TDT.

Keywords: depression, chronic fatigue syndrome, inflammation, cytokines, neuroimmune, biomarkers.

2

Introduction

Beta-thalassemia (β-TM) encompasses a group of hereditary conditions characterized by the absence or deficiency of the β-globin chain in the hemoglobin A molecule. This chain defect causes harm to the erythrocyte membrane and ultimately leads to anemia (Raguram et al., 2022). The aforementioned condition often presents with symptoms of hemolytic anemia and has a 15% mortality rate among the millions of children it impacts (Raguram et al., 2022, Crippa et al., 2019). Individuals with β-TM necessitate long-term blood transfusions to maintain adequate hemoglobin levels and mitigate the adverse consequences of erythropoiesis inefficiency (Aydinok, 2020). Transfusion-dependent thalassemia (TDT) patients are at risk of developing various complications because of requiring frequent blood transfusions (Shah et al., 2019). Prolonged blood transfusions have the potential to cause substantial iron overload (IO), which can result in toxicity affecting various organs such as the heart, liver, and endocrine glands (Hamed et al., 2016, Daher et al., 2017). Iron in excess has been found to be neurotoxic due to its capacity to trigger oxidative stress within the brain (Schipper, 2004). Neuronal death and neurodegeneration (Schneider and Bhatia, 2013), neuroinflammation, Parkinson's disease and Alzheimer's disease (Stankiewicz et al., 2007, Hagemeier et al., 2012), neuropsychiatric disorders including affective symptoms and chronic fatigue syndrome (CFS) (Beard et al., 2005, Maaroufi et al., 2009, Al-Hakeim et al., 2020, Al-Hakeim et al., 2021), and cognitive impairments (Wang, 2013) are all potential consequences of IO in the brain. Neuroprotection may result from the use of iron chelators to decrease excessive iron deposition (Ward et al., 2014).

Thalassemia is associated with a heightened prevalence of neuropsychiatric disorders (Sahu et al., 2023). Around sixty-five percent (Sahu et al., 2023) to eighty-three percent (Shaligram et al., 2007) of children with thalassemia may suffer from anxiety disorders, depression, or oppositional defiant disorder. Anxiety symptoms were present in 32% of thalassemia patients and major depression (MDD) in 16-31% (Gan et al., 2016, Shafiee et al., 2014). MDD is associated with

elevated IO and pro-inflammatory cytokine levels in the serum, such as interleukin (IL)-1β and tumor necrosis factor (TNF)-α, which are indicators of immune activation in TDT children (Al-Hakeim et al., 2020). Blood transfusions may induce depressive symptoms and MDD in TDT via the mediating effects of IO and subsequent activation of the immune-inflammatory response system (IRS), according to the conclusion reached by the latter authors. MDD has been linked to alterations in iron metabolism, as indicated by elevated serum ferritin levels, decreased erythrocyte count, and decreased hematocrit and hemoglobin concentrations (Rybka et al., 2013, Trevisan et al., 2016).

Additionally, evidence suggests that the impacts of activated IRS pathways on MDD (Schiepers et al., 2005, Maes, 2008, Maes et al., 2022b, Al-Hakeim et al., 2020) and CFS are mediated by heightened neurotoxicity (Maes et al., 2022a). MDD is distinguished by increased concentrations of neurofilament light chain (NFL), glial fibrillary acidic protein (GFAP), P-tau217, and IRS biomarkers including C-reactive protein (CRP) (Al-Hakeim et al., 2023a). NFL levels are elevated not only in patients with MDD and bipolar disorder (Al-Hakeim et al., 2020, Chen et al., 2022) but also in those with treatment-resistant depression (Domingues et al., 2019, Spanier et al., 2019). Serum concentrations of NFL, nestin, CRP, and IL-10 are increased in patients with end-stage renal disease, while serum levels of zinc levels are reduced in comparison to the control group (Al-Hakeim et al., 2023b). NFL is a biomarker of neuronal injury and neurodegenerative processes in the central nervous system (CNS), whilst neurodegenerative diseases are frequently associated with elevated NFL plasma levels (Maes et al., 2022c, Yuan and Nixon, 2016). GFAP serves as an indicator of astrocyte functionality, and both its upregulation and rearrangement are crucial factors in the pathogenesis and progression of neurodegeneration, ischemic stroke, and various other CNS disorders (Bagheri et al., 2022, Hol and Pekny, 2015, Yang and Wang, 2015). Two other neuronal injury biomarkers that were not explored in TDT are nestin and neuron-specific enolase (NSE). Nestin mediates radial axonal growth and is an additional intermediate filament protein that is expressed by neuronal progenitor cells, including those in the adult brain (Hendrickson et al., 2011,

Paquet-Durand and Bicker, 2007). NSE is an additional neuronal marker that has been linked to neurodegenerative, inflammatory, hypoxic, and metabolic diseases (Park et al., 2019, Bagheri et al., 2022, Haque et al., 2018).

Additionally, magnesium deficiency may contribute to neurodegenerative processes (Hlásný, 2020), and dysfunctional calcium signaling may be one of the essential processes in neurodegenerative processes (Bezprozvanny, 2010). This is significant because IRS activation is associated with decreased calcium, magnesium, and zinc levels and increased copper levels in MDD (Al-Dujaili et al., 2019, Al-Hakeim et al., 2022). Neurodegenerative pathways, including aberrations in the Wnt/catenin pathway, oxidative stress pathways, and IRS activation, may be implicated in CFS (Maes et al., 2022a).

Therefore, we postulated that IO could potentially induce heightened neurotoxicity and, consequently, increased levels of neuronal and astroglial projection lesions in TDT, thereby exacerbating the severity of affective symptoms and CFS. Therefore, the primary objective of the present investigation is to determine whether TDT is correlated with neuronal and astroglial injury indicators (as measured by serum GFAP, NSE, NFL, and nestin), as well as whether these indicators are associated with IRS biomarkers (as measured by CRP, IL-6, and IL-10), affective symptoms, and CFS.

Subjects and Methods

Participants

A total of 167 children were enrolled in the present study; of these, 126 were children with TDT and forty-one were healthy control children between the ages of 6 and 12, of both sexes. The recruitment process for TDT patients commenced in March 2023 and concluded in May 2023 at the Thalassemia Unit, which is situated at Al-Zahra'a Teaching Hospital in the Najaf Governorate of Iraq. The diagnosis of β -TM was ascertained through the utilization of the diagnostic criteria

6

specified in the 2019 ICD-10-CM Diagnosis Code D56.1 by pediatricians and hematologists. The identification of β -TM was accomplished through the assessment of distinctive clinical manifestations, including aberrant bone growth, hepatosplenomegaly, and severe anemia. Hematological assessments were performed, including the measurement of hemoglobin (Hb) concentrations below 70 g/L and the identification of a high proportion of reticulocytes and hypochromic microcytic red blood cells with anisopoikilocytosis. Furthermore, the concentration of HbA2 was ascertained via high-performance liquid chromatography (HPLC) employing the VARIANT TM β -Thalassemia Short Program.

The control group comprised forty-one infants who were in good health. There were no cases of anemia, immune-inflammatory disorders, or systemic diseases among the controls. Children with splenectomy, systemic diseases including renal failure, or diabetes mellitus were precluded from the study. The determination of when to administer packaged red blood cells (RBCs) for blood transfusions was based on the Hb levels, which had to be maintained at or above 90 g/L. This was accomplished every two to four weeks. Furthermore, a protocol of iron-chelating therapy was implemented for the patients. This involved administering deferoxamine mesylate USP (brand name Desferal®) infusions at a rate ranging from 25 to 50 mg/kg/day for a duration of eight hours daily. The precise dosage that was administered to the patients was ascertained by analyzing their blood ferritin levels. To alleviate the symptoms of ineffective erythropoiesis, folic acid was administered to most patients undergoing TDT. Vitamin C was administered to patients who had received a diagnosis of TDT as a therapeutic intervention to support the iron chelation process when used in conjunction with deferoxamine.

The researchers obtained written informed consent from the first-degree relatives (either the father or mother) of the participating children after a comprehensive verbal explanation, in adherence to the tenets delineated in the Declaration of Helsinki. The research was granted approval by the

Institutional Review Board (IRB) of the Najaf Health Directorate, Training and Human Development Center, Iraq (document number 4233/2023).

Clinical measurements

The Fibro-fatigue (FF) scale was administered by a senior psychiatrist to evaluate the severity of CFS in both patients and controls (Zachrisson et al., 2002). The assessment of depressive symptoms was conducted utilizing the Children's Depression Inventory (CDI). This is a self-rating screening instrument consisting of twenty-seven three-point scale statements. The child is requested to choose the response that most accurately characterizes his or her emotions over the past two weeks in relation to each given statement. The total CDI score is utilized as an indicator of depression severity in the present study. Negative self-esteem, interpersonal difficulties, ineffectiveness, anhedonia, and negative mood are the subscales that comprise the CDI. Having been validated in school-aged children, the CDI is one of the most widely utilized depression screening instruments for children. Depression in children may be diagnosed when the Child Depression Inventory (CDI) score is equal to or greater than nineteen. The children's anxiety symptoms were assessed using the Spence Children's Anxiety Scale (SCAS) (Spence et al., 2003).

Assays

Five milliliters of venous blood were drawn from all participants after an overnight fast. The patients' samples were collected just before their blood transfusion session. Blood was left until complete clotting (about ten minutes) at room temperature. After centrifugation for five minutes at 3000 rpm, serum was separated and transported into Eppendorf tubes. Serum calcium, magnesium, albumin, copper, and zinc were measured by using ready-for-use kits purchased from Agappe Diagnostics[®] ready-to-use kit from (Switzerland). Cham Copper was determined spectrophotometrically using a kit from LTA Co. (Milano, Italy). The amount of iron in sera was determined by colorimetric kits purchased from Spectrum® (Cairo, Egypt). Commercial ELISA

sandwich kits provided by Nanjing Pars Biochem Co., Ltd., Nanjing, China, were used to measure interleukin-6, Interleukin-10, GFAP, NSE, NF-L, and nestin. Serum ferritin levels were measured by using an ELISA kit purchased from Elabscience® (Wuhan, China). These kits were made for human samples depending on the biotin double antibody sandwich technology. Hematological parameters were measured by a five-part differential Mindray BC-5000 hematology analyzer (Mindray Medical Electronics Co., Shenzhen, China). The inter-assay CV% of all kits is lower than 10%. For samples with highly concentrated analytes, we employed sample dilutions. A C-reactive protein (CRP) latex slide test (Spinreact®, Barcelona, Spain) was used for CRP measurement in human serum. The approximate CRP concentration in the patient sample is calculated as follows: 6 x CRP Titer = mg/L.

Statistical analysis

Analysis of contingency tables (χ^2 test) was employed to examine the relationships between nominal variables, whereas analysis of variance (ANOVA) was utilized to assess variations in continuous variables across groups. To determine the correlations between scale variables, Pearson's product-moment correlation coefficients were applied. General linear models (GLM) were employed in the current investigation to assess the correlations between TDT (in contrast to the control group) and the biomarkers. Following that, evaluations of between-subject relationships and pairwise comparisons were performed across treatment groups. The researchers utilized a false-discovery rate (FDR) procedure to mitigate the impact of type I errors that may occur during multiple comparisons (Benjamini and Hochberg, 1995). Multiple regression analysis was utilized in the study, employing both manual and automatic stepwise techniques. A p-to-entry threshold of 0.05 and a p-to-remove threshold of 0.06 were applied. The purpose of the analysis was to determine which biomarkers could be used to predict the scores by assessing the variation in R^2 (used as effect size). To identify (multi)collinearity issues, tolerance, and VIF were employed, Cook's distance and leverage were utilized to assess multivariate normality, and the White and modified Breusch-Pagan tests were

utilized to determine homoscedasticity. The results of the regression analyses were bootstrapped using 5,000 samples, and when there was an incongruity between the outcomes, the bootstrapped results were displayed. Four z-unit-based composite ratings were computed. a) IRS activation was calculated as z IL-6 + z IL-10 + z CRP - z zinc - z albumin (referred to as Comp_IRS); b) Disorders in the erythron were represented by z hemoglobin + z hematocrit (labeled as Comp_erythron); c) z Iron + z ferritin constituted Comp_IO; and d) an overall severity index was determined as z FF + z CDI + z SCAS (labeled as Comp_severity). We extracted the first principal component (PC) using the principal component (GFAP), NSE, and Nestin (NFL could not be included because it did not load significantly on the first PC). The first principal component (PC) accounted for 50.3% of the variance, and all loadings exceeded 0.67. These results suggest that the PC score, designated PC_neuronal, potentially reflects neuronal injury. All statistical tests were two-tailed, and a p-value of 0.05 was used for statistical significance. For the analysis of the data, version 29 of IBM SPSS for Windows was utilized.

Results

1. Socio-demographic data

Table 1 shows the socio-demographic and clinical data of the children participating in the current study. The TDT patients have a duration of disease (appearance of severe symptoms) of 8.84±2.75 years. There were no significant differences in age, sex ratio, BMI, and education years between healthy children and TDT patients. The results showed significant increases (all p<0.001) in total FF, CDI, and SCAS scores, ferritin, and iron in TDT patients compared with healthy children. There was a significant decrease in Hb and PCV% in patients compared with the controls.

2. Biomarkers in TDT and controls

Table 2 shows the results of the biomarkers in TDT and control groups. The results showed a significant increase in the serum CRP, copper, IL-6, IL-10, NSE, GFAP, and NFL in the TDT group

compared with the healthy children. The Comp_IRS and PC_neuronal scores were both significantly increased in TDT patients compared with the control group. Magnesium, calcium, and zinc are significantly decreased in TDT compared with the control group. These differences remained significant after FDR's p-correction. Serum albumin and nestin are not significantly different between the diagnostic groups.

3. Correlation matrix between clinical scores and biomarkers in TDT

Table 3 shows the correlation matrix of the neuropsychiatric rating scale scores and the iron status biomarkers in TDT patients. The results showed that FF is significantly correlated with CRP, copper, IL-6, IL-10, GFAP, and NFL, whilst there is a significant inverse correlation between FF and magnesium, calcium, and zinc. The results indicated that the CDI score is significantly correlated with CRP, IL-10, NSE, GFAP, and NFL, and inversely with magnesium, calcium, and zinc. The SCAS score is significantly correlated with CRP, copper, IL-10, and NFL, and inversely with calcium and zinc. The Comp_erythron index was significantly and inversely correlated with CRP, copper, IL-6, IL-10, NSE, GFAP, and NFL, and positively with magnesium, calcium, and zinc. Comp_IO is significantly correlated with CRP, copper, IL-6, IL-10, NSE, GFAP, and NFL, and inversely with magnesium and calcium.

There were significant correlations between Comp_severity and Comp_IRS (r=0.349, p<0.001), Comp_IO (r=0.275, p<0.001) and Comp_erythron (r=-0.221, p<0.001).

4. Prediction of neuropsychiatric scores

Table 4 shows the results of multiple regression analyses with the total FF, CDI, and SCAS scores as dependent variables and the neuronal damage biomarkers and other biomarkers as explanatory variables. The first regression shows that 42.9% of the variance in the FF score was predicted by CRP, copper, and NFL (all positively), and calcium and magnesium (both inversely

associated). Regression #2 shows that the CDI total score was predicted by CRP, IL-10, and NFL (all three positively) and inversely with calcium. The third regression shows that 23.2% of the variance in the SCAS total score was explained by NFL, CRP, and copper (all positively correlated), and zinc (inversely associated). **Figure 1** shows the partial regression of the total SCAS scale score on NFL levels.

5. Prediction of the neuronal damage biomarkers by the measured biomarkers in TDT patients.

The results in **Table 5** reveal that neuronal damage biomarkers may be predicted by IRS biomarkers. Regression #1 shows that 9.5% of the variance in the NSE could be explained by IL-10. In Regression #2, a part of the variance (12.6 7%) in GFAP is explained by IL-6 and IL-10. **Figure 2** shows the partial regression of GFAP on Comp_IRS. The third regression shows that 16.5% of the variance in NFL is explained by copper (positively) and hemoglobin (inversely). **Figure 3** shows the regression of the NFL levels on hemoglobin. Regression #4 shows that 10.6% of the variance in nestin is positively associated with IL-6 and inversely with calcium. In Regression #5, a moderate part of the variance (24.2%) in PC_neuronal was explained by IL-6, IL-10, and ferritin. Regression #6 shows that 27.1% of the variance in Comp_IRS could be explained by ferritin and inversely by PCV%. **Figure 4** shows the partial regression of Comp_IRS on Comp_erythron.

Discussion

IO, IRS activation, and affective and CFS symptoms due to TDT

The first major finding of this research is that children with TDT have higher total FF, CDI, and SCAS scores in comparison to healthy children. Additionally, there is a significant correlation between the integrated index of severity of affective and CFS symptoms and IRS activation (increased CRP, IL-6 and IL-10, and lowered zinc), IO (increased iron and ferritin), and erythron disorders (lowered hematocrit and hemoglobin).

IRS activation in TDT was identified in the present study by elevated levels of CRP, IL-6, and IL-10 in the serum, in comparison to the control group. Previously, a wide spectrum of immune defects has been observed in patients with affective disorders and CFS (Maes and Carvalho, 2018, Maes et al., 2022a) and β-thalassemic patients (Bazi et al., 2018). Serum concentrations of IL-6, IL-10, and ferritin were all elevated in TDT patients (Politou et al., 2020). TDT has been associated with altered cytokine profiles, modifications in innate immune functions, and the manifestation of a low-grade systemic inflammatory state (Elsayh et al., 2016). Based on existing literature data, immunological abnormalities observed in thalassemia patients may be induced by both the condition and its therapeutic interventions. IO, functional abnormalities of immune system cells caused by chronic inflammation, oxidative stress, multiple blood transfusions, iron chelation therapy, and splenectomy are the most significant contributors to these changes (Gluba-Brzózka et al., 2021).

Depressive and CFS symptoms may result from peripheral activation of IRS pathways influencing the brain via humoral and neural pathways, thereby altering the functions of neural cells, structural and functional connectivity, and ultimately leading to neuropsychiatric symptoms (Kubera et al., 2011, Harrison et al., 2016, Maes et al., 2022a). Neurotoxicity can be caused by various neuro-immune (M1, Th1, and Th17) and neuro-oxidative pathways. This can disrupt crucial neuronal processes, including neurogenesis, neuroplasticity, axonogenesis, dendritic sprouting, and receptor expression (Maes et al., 2022b, Maes et al., 2009). Furthermore, IRS activation disrupts interoceptive signaling and the functional connectivity within the brain networks, which may have ramifications for the etiology of MDD and CFS (Aruldass et al., 2021, Maes et al., 2022b). In addition, heightened concentrations of proinflammatory cytokines trigger an acute phase response in the liver, resulting in augmented CRP production (Sluzewska et al., 1996). This compound further impairs endothelial cells, increasing their permeability and exacerbating the progression of neurodegenerative and cerebrovascular disorders (Aruldass et al., 2021, Hsuchou et al., 2012, Belin et al., 2020, Ge et al., 2013).

Another hypothesis that connects TDT with the development of affective and CFS symptoms is that iron accumulation in certain brain regions has neurotoxic effects. Iron accumulation not only triggers oxidative stress but also exerts an impact on the turnover of neurotransmitters and the expression of neuroreceptors within the brain, consequently influencing behavioral responses (Al-Hakeim et al., 2020, Cutler, 1994, Kim and Wessling-Resnick, 2014). Impaired dopamine metabolism, including dopamine transporters and increased dopamine D2 receptors (Chang et al., 2014), as well as decreased brain serotonin and dopamine concentrations (Elseweidy and Abd El-Baky, 2008), may contribute to the emotional symptoms and behavioral deficits associated with IO. Iron has a direct impact on GABAergic pathways, as do reactive oxygen species catalyzed by iron (Ye et al., 2019), (Accardi, 2016). Given that an overabundance of iron induces the generation of reactive oxygen species (Farina et al., 2013), and that increased oxidative stress is associated with dysfunction in the GABAergic system (Han et al., 2016), the hypothesis proposes that iron accumulation in the brain disrupts GABA homeostasis and impacts affective behavior (Ye et al., 2019). Additionally, fear of separation from family, limited social interaction and isolation, physical and facial deformities, restricted life opportunities, fear of death, maladaptive coping mechanisms, and restrictions in school and outdoor pursuits are all contributing factors to affective disorders in children with TDT (Shah et al., 2020, Koutelekos and Haliasos, 2013).

Neuronal and astroglial projection toxicity in TDT

The second major finding of the present study is that serum levels of various neuronal and astroglial damage biomarkers are elevated in TDT patients relative to the control group and that these CNS injury biomarkers are positively associated with the severity of affective and CFS symptoms. NFL, GFAP, and NSE were, in descending order of significance, the most pertinent CNS biomarkers. Moreover, there exists a substantial correlation between these markers of CNS injury and IRS biomarkers, as well as copper, IO, or erythron biomarkers.

Elevated NFL levels in patients with neuroinflammatory diseases are indicative of ongoing and acute disease processes as opposed to progressive brain injury (Cantó et al., 2019, Srpova et al., 2021). Moreover, synaptic degeneration may be indicated by an increase in NFL (Zerr et al., 2018), which is a biomarker of injury to cyto-axonal cell structures (Gaetani et al., 2019) in neurodegenerative disorders. The correlation between serum NFL and cognitive performance in healthy individuals suggests that NFL has the capability to detect subclinical microstructural alterations (Beste et al., 2019). Reactive astrogliosis and CNS trauma induce an increase in GFAP expression, which may be translocated into the peripheral circulation via blood-brain-barrier disruption (Yang and Wang, 2015, Hol and Pekny, 2015). Elevated serum GFAP is, therefore, a biomarker for neurotoxicity, specifically injury to neuronal and astroglial cells (Yang and Wang, 2015). Variations in GFAP levels can manifest in response to traumatic injuries, neurodegenerative or neuroinflammatory processes (Bagheri et al., 2015, Abdelhak et al., 2019), neuropathology (Wang and Parpura, 2016), disruption of the blood-brain barrier (Torres-Platas et al., 2016), and brain vascular inflammation. Serum and cerebrospinal fluid NSE elevation is an effective biomarker for neuronal loss and impairment, brain injury, and neuroinflammation (Park et al., 2019, Bagheri et al., 2022, Haque et al., 2018). It is noteworthy that an increase in the release of neuronal biomarkers into the bloodstream (Arslan and Zetterberg, 2023, Negi et al., 2023) through the glymphatic system may result from apoptosis of brain cells (Hablitz and Nedergaard, 2021, Plog et al., 2015).

Patients diagnosed with MDD and those experiencing affective and CFS symptoms because of end stage renal disease exhibit elevated levels of neuronal and astroglial projection markers (Al-Hakeim et al., 2023b, Al-Hakeim et al., 2023a). Cognitive function was found to be inversely correlated with increased NFL in patients with MDD (Bavato et al., 2021). This finding suggests that active neuropathological processes, specifically axonal and synaptic lesions, may be present in these patients (Douillard-Guilloux et al., 2013, Dohm et al., 2017). CSF GFAP levels are elevated in patients with MDD (Michel et al., 2021), and serum GFAP levels may increase as the severity of

MDD worsens (Steinacker et al., 2021). Additionally, individuals with neuropsychiatric disorders who do not exhibit any brain radiological abnormalities may have elevated plasma GFAP levels (Esnafoglu et al., 2017). Serum GFAP has been proposed as a potential marker for monitoring astroglial pathology in MDD (Hol and Pekny, 2015, Al Shweiki et al., 2017, Steinacker et al., 2021). It was believed that NSE and GFAP serve as prognostic indicators for high-risk suicide attempters (Bagheri et al., 2022). Furthermore, elevated CRP levels were found to be strongly correlated with increases in these neuronal and astroglial projection injury biomarkers in MDD (Al-Hakeim et al., 2023a). In summary, the findings indicate that the heightened neurotoxicity observed in affective and CFS symptoms might be the result of IRS activation and neuroimmune mechanisms. In the following paragraph, however, we explore additional potential pathways that connect TDT with CNS injury.

An overabundance of iron within the brain has been associated with the onset and progression of neurodegenerative diseases (Bartzokis et al., 2000, Rouault and Cooperman, 2006). Elevated concentrations of iron stimulate the production of reactive oxygen species, which subsequently cause harm to cells and tissues (Nandar et al., 2013, Tuomainen et al., 2007) as well as neurodegenerative disorders (Honda et al., 2004, Xian-hui et al., 2015). Iron toxicity can induce neurodegeneration, which in turn can trigger ferroptosis, a non-apoptotic cell death specific to iron (Kenkhuis, 2022, Zhang et al., 2020). In addition to heightened neuro-oxidative pathways, thalassemia disease may also induce neurodegeneration via mitochondrial dysfunctions (Shaki et al., 2017). Lowered calcium levels, in addition to peripheral inflammation, have the potential to induce neuro-glial projection toxicity (Al-Hakeim et al., 2023a).

Limitations of the study.

The fact that this is a case-control study is an initial limitation; consequently, any potential causal relationships established here must be checked in prospective studies. Furthermore, to make the study even more interesting, we should have assessed a comprehensive range of cytokines and

biomarkers associated with neuronal damage in TDT children in conjunction with neuropsychiatric

ratings.

Conclusions

The current investigation showed heightened neurotoxicity among TDT patients, in which

immune-inflammatory biomarkers and serum biomarkers of injury to neuronal and astroglial

projections are correlated with the intensity of affective and CFS symptoms. IO may induce both

immune activation and increased neurotoxicity in TDT. Activated IRS pathways, increased

neurotoxicity, and subsequent injury to neuronal and astroglial projections are, therefore, new drug

targets for the treatment and prevention of affective and CFS symptoms caused by IO and TDT,

according to this study. In addition to enhancing neuroprotection, novel pharmaceutical interventions

should be developed to target neurotoxicity and IRS activation.

Acknowledgment

We thank the staff of the Thalassemia Unit at Al-Zahra'a Teaching Hospital-Najaf city-Iraq

for their help in the collection of samples. We also acknowledge the work of the highly skilled staff

of the Asia Laboratory in measuring the biomarkers.

Funding

There was no specific funding for this specific study.

Conflict of interest

The authors have no conflict of interest with any commercial or other association in connection.

17

with the submitted article.

Author's contributions

All the contributing authors have participated in the preparation of the manuscript.

References

- ABDELHAK, A., HOTTENROTT, T., MORENAS-RODRÍGUEZ, E., SUÁREZ-CALVET, M., ZETTL, U. K., HAASS, C., MEUTH, S. G., RAUER, S., OTTO, M. & TUMANI, H. 2019. Glial activation markers in CSF and serum from patients with primary progressive multiple sclerosis: potential of serum GFAP as disease severity marker? *Frontiers in neurology*, 10, 280.
- ACCARDI, M. V. 2016. Regulation of inhibitory GABAergic synapses by reactive oxygen species, McGill University (Canada).
- AL-DUJAILI, A. H., AL-HAKEIM, H. K., TWAYEJ, A. J. & MAES, M. 2019. Total and ionized calcium and magnesium are significantly lowered in drug-naïve depressed patients: effects of antidepressants and associations with immune activation. *Metab Brain Dis*, 34, 1493-1503.
- AL-HAKEIM, H. K., AL-NAQEEB, T. H., ALMULLA, A. F. & MAES, M. 2023a. The physio-affective phenome of major depression is strongly associated with biomarkers of astroglial and neuronal projection toxicity which in turn are associated with peripheral inflammation, insulin resistance and lowered calcium. *Journal of Affective Disorders*, 331, 300-312.
- AL-HAKEIM, H. K., HADI, H. H., JAWAD, G. A. & MAES, M. 2022. Intersections between copper, β-arrestin-1, calcium, FBXW7, CD17, insulin resistance and atherogenicity mediate depression and anxiety due to type 2 diabetes mellitus: A nomothetic network approach. *J Personal Med*, 12, 23.
- AL-HAKEIM, H. K., NAJM, A. H., AL-DUJAILI, A. H. & MAES, M. 2020. Major Depression in Children with Transfusion-Dependent Thalassemia Is Strongly Associated with the Combined Effects of Blood Transfusion Rate, Iron Overload, and Increased Pro-inflammatory Cytokines. *Neurotox Res*, 38, 228-241.
- AL-HAKEIM, H. K., NAJM, A. H., MOUSTAFA, S. R. & MAES, M. 2021. Construction of an exposure-pathway-phenotype in children with depression due to transfusion-dependent thalassemia: results of (un) supervised machine learning. *Journal of Affective Disorders*, 282, 644-655.
- AL-HAKEIM, H. K., TWAIJ, B. A. A.-R., AHMED, M. H., ALMULLA, A. F., MOUSTAFA, S. R. & MAES, M. 2023b. In end-stage kidney disease, inflammation, erythron abnormalities and declined kidney function tests are accompanied by increased affective symptoms, chronic-fatigue, and fibromyalgia. *medRxiv*, 2023.01. 12.23284460.
- AL SHWEIKI, M. R., OECKL, P., STEINACKER, P., HENGERER, B., SCHÖNFELDT-LECUONA, C. & OTTO, M. 2017. Major depressive disorder: insight into candidate cerebrospinal fluid protein biomarkers from proteomics studies. *Expert Rev Proteomics*, 14, 499-514.
- ARSLAN, B. & ZETTERBERG, H. 2023. Neurofilament light chain as neuronal injury marker—what is needed to facilitate implementation in clinical laboratory practice? *Clinical Chemistry and Laboratory Medicine (CCLM)*, 61, 1140-1149.
- ARULDASS, A. R., KITZBICHLER, M. G., MORGAN, S. E., LIM, S., LYNALL, M.-E., TURNER, L., VERTES, P., CAVANAGH, J., COWEN, P. & PARIANTE, C. M. 2021. Dysconnectivity of a brain functional network was associated with blood inflammatory markers in depression. *Brain Behav Immun*, 98, 299-309.
- AYDINOK, Y. 2020. Treatment of thalassaemia: a review of the new approaches on transfusion safety and the novel therapeutics. *ISBT Science Series*, 15, 102-109.
- BAGHERI, M., GHANEIALVAR, H., OSHNOKHAH, M. & SALARI, S. 2022. GFAP and neuron specific enolase (NSE) in the serum of suicide attempters. *Medical journal of the Islamic Republic of Iran*, 36.
- BAGHERI, M., REZAKHANI, A., ROGHANI, M., JOGHATAEI, M. T. & MOHSENI, S. 2015. Protocol for three-dimensional confocal morphometric analysis of astrocytes. *JoVE (Journal of Visualized Experiments)*, e53113.

- BARTZOKIS, G., SULTZER, D., CUMMINGS, J., HOLT, L. E., HANCE, D. B., HENDERSON, V. W. & MINTZ, J. 2000. In vivo evaluation of brain iron in Alzheimer disease using magnetic resonance imaging. *Archives of general psychiatry*, 57, 47-53.
- BAVATO, F., CATHOMAS, F., KLAUS, F., GUTTER, K., BARRO, C., MACESKI, A., SEIFRITZ, E., KUHLE, J., KAISER, S. & QUEDNOW, B. B. 2021. Altered neuroaxonal integrity in schizophrenia and major depressive disorder assessed with neurofilament light chain in serum. *J Psychiat Res*, 140, 141-148.
- BAZI, A., SHAHRAMIAN, I., YAGHOOBI, H., NADERI, M. & AZIZI, H. 2018. The role of immune system in thalassemia major: a narrative review. *Journal of Pediatrics Review*, 6, 29-36
- BEARD, J. L., HENDRICKS, M. K., PEREZ, E. M., MURRAY-KOLB, L. E., BERG, A., VERNON-FEAGANS, L., IRLAM, J., ISAACS, W., SIVE, A. & TOMLINSON, M. 2005. Maternal iron deficiency anemia affects postpartum emotions and cognition. *The Journal of nutrition*, 135, 267-272.
- BELIN, C., DEVIC, P., AYRIGNAC, X., DOS SANTOS, A., PAIX, A., SIRVEN-VILLAROS, L., SIMARD, C., LAMURE, S., GASTINNE, T., URSU, R., BERGER, C., PLATON, L., TESSOULIN, B., AZOULAY, E., WALLET, F., THIEBLEMONT, C., BACHY, E., CARTRON, G., LAPLAUD, D. A. & CARPENTIER, A. F. 2020. Description of neurotoxicity in a series of patients treated with CAR T-cell therapy. *Sci Rep*, 10, 18997.
- BENJAMINI, Y. & HOCHBERG, Y. 1995. Controlling the false discovery rate: a practical and powerful approach to multiple testing. *Journal of the Royal statistical society: series B* (*Methodological*), 57, 289-300.
- BESTE, C., STOCK, A.-K., ZINK, N., OCKLENBURG, S., AKGUN, K. & ZIEMSSEN, T. 2019. How minimal variations in neuronal cytoskeletal integrity modulate cognitive control. *NeuroImage*, 185, 129-139.
- BEZPROZVANNY, I. 2010. Calcium signaling and neurodegeneration. *Acta Naturae*, 2, 72-80.
- CANTó, E., BARRO, C., ZHAO, C., CAILLIER, S. J., MICHALAK, Z., BOVE, R., TOMIC, D., SANTANIELLO, A., HäRING, D. A. & HOLLENBACH, J. 2019. Association between serum neurofilament light chain levels and long-term disease course among patients with multiple sclerosis followed up for 12 years. *JAMA neurology*, 76, 1359-1366.
- CHANG, J., KUEON, C. & KIM, J. 2014. Influence of lead on repetitive behavior and dopamine metabolism in a mouse model of iron overload. *Toxicological research*, 30, 267-276.
- CHEN, M.-H., LIU, Y.-L., KUO, H.-W., TSAI, S.-J., HSU, J.-W., HUANG, K.-L., TU, P.-C. & BAI, Y.-M. 2022. Neurofilament light chain is a novel biomarker for major depression and related executive dysfunction. *Int J Neuropsychopharmacol*, 25, 99-105.
- CRIPPA, S., ROSSELLA, V., APRILE, A., SILVESTRI, L., RIVIS, S., SCARAMUZZA, S., PIRRONI, S., AVANZINI, M. A., BASSO-RICCI, L. & HERNANDEZ, R. J. 2019. Bone marrow stromal cells from β-thalassemia patients have impaired hematopoietic supportive capacity. *The Journal of clinical investigation*, 129, 1566-1580.
- CUTLER, P. 1994. Iron overload and psychiatric illness. *The Canadian Journal of Psychiatry*, 39, 8-11.
- DAHER, R., MANCEAU, H. & KARIM, Z. 2017. Iron metabolism and the role of the iron-regulating hormone hepcidin in health and disease. *La Presse Médicale*, 46, e272-e278.
- DOHM, K., REDLICH, R., ZWITSERLOOD, P. & DANNLOWSKI, U. 2017. Trajectories of major depression disorders: a systematic review of longitudinal neuroimaging findings. *Aust NZ J Psychiatry*, 51, 441-454.
- DOMINGUES, R. B., FERNANDES, G. B. P., LEITE, F. & SENNE, C. 2019. Neurofilament light chain in the assessment of patients with multiple sclerosis. *Arg Neuropsiquiatr*, 77, 436-441.
- DOUILLARD-GUILLOUX, G., GUILLOUX, J.-P., LEWIS, D. A. & SIBILLE, E. 2013. Anticipated brain molecular aging in major depression. *Am J Geriat Psychiatry*, 21, 450-460.

- ELSAYH, K. I., MOHAMMED, W. S., ZAHRAN, A. M. & SAAD, K. 2016. Leukocytes apoptosis and adipocytokines in children with beta thalassemia major. *Clinical and experimental medicine*, 16, 345-350.
- ELSEWEIDY, M. M. & ABD EL-BAKY, A. E. 2008. Effect of dietary iron overload in rat brain: oxidative stress, neurotransmitter level and serum metal ion in relation to neurodegenerative disorders.
- ESNAFOGLU, E., AYYıLDıZ, S. N., CıRRıK, S., ERTURK, E. Y., ERDIL, A., DAGLı, A. & NOYAN, T. 2017. Evaluation of serum Neuron-specific enolase, S100B, myelin basic protein and glial fibrilliary acidic protein as brain specific proteins in children with autism spectrum disorder. *Int J Dev Neurosci*, 61, 86-91.
- FARINA, M., AVILA, D. S., DA ROCHA, J. B. & ASCHNER, M. 2013. Metals, oxidative stress and neurodegeneration: a focus on iron, manganese and mercury. *Neurochem Int*, 62, 575-94.
- GAETANI, L., BLENNOW, K., CALABRESI, P., DI FILIPPO, M., PARNETTI, L. & ZETTERBERG, H. 2019. Neurofilament light chain as a biomarker in neurological disorders. *J Neurol Neurosurg Psychiatry*, 90, 870-881.
- GAN, G. G., HUE, Y. L. & SATHAR, J. 2016. Factors Affecting Quality of Life in Adult Patients with Thalassaemia Major and Intermedia. *Ann Acad Med Singap*, 45, 520-523.
- GE, X., XU, X.-Y., FENG, C.-H., WANG, Y., LI, Y.-L. & FENG, B. 2013. Relationships among serum C-reactive protein, receptor for advanced glycation products, metabolic dysfunction, and cognitive impairments. *BMC Neurology*, 13, 110.
- GLUBA-BRZÓZKA, A., FRANCZYK, B., RYSZ-GÓRZYŃSKA, M., ROKICKI, R., KOZIARSKA-ROŚCISZEWSKA, M. & RYSZ, J. 2021. Pathomechanisms of Immunological Disturbances in β-Thalassemia. *International Journal of Molecular Sciences*, 22, 9677.
- HABLITZ, L. M. & NEDERGAARD, M. 2021. The glymphatic system: a novel component of fundamental neurobiology. *Journal of Neuroscience*, 41, 7698-7711.
- HAGEMEIER, J., GEURTS, J. J. & ZIVADINOV, R. 2012. Brain iron accumulation in aging and neurodegenerative disorders. *Expert review of neurotherapeutics*, 12, 1467-1480.
- HAMED, A. A., ELGUINDY, W., ELHENAWY, Y. I. & IBRAHIM, R. H. 2016. Early cardiac involvement and risk factors for the development of arrhythmia in patients with β-thalassemia major. *Journal of pediatric hematology/oncology*, 38, 5-11.
- HAN, M., CHANG, J. & KIM, J. 2016. Loss of divalent metal transporter 1 function promotes brain copper accumulation and increases impulsivity. *Journal of neurochemistry*, 138, 918-928.
- HAQUE, A., POLCYN, R., MATZELLE, D. & BANIK, N. L. 2018. New insights into the role of neuron-specific enolase in neuro-inflammation, neurodegeneration, and neuroprotection. *Brain sciences*, 8, 33.
- HARRISON, N. A., VOON, V., CERCIGNANI, M., COOPER, E. A., PESSIGLIONE, M. & CRITCHLEY, H. D. 2016. A neurocomputational account of how inflammation enhances sensitivity to punishments versus rewards. *Biol Psychiatry*, 80, 73-81.
- HENDRICKSON, M. L., RAO, A. J., DEMERDASH, O. N. & KALIL, R. E. 2011. Expression of nestin by neural cells in the adult rat and human brain. *PloS one*, 6, e18535.
- HLáSNý, J. 2020. Is magnesium deficiency the cause of neurodegeneration in animals and humans? 2nd part; Alzheimer's disease and BSE magnesium-ammonia theory connections. *V'yzkum v chovu skotu*, 2, 28-39.
- HOL, E. M. & PEKNY, M. 2015. Glial fibrillary acidic protein (GFAP) and the astrocyte intermediate filament system in diseases of the central nervous system. *Current opinion in cell biology*, 32, 121-130.
- HONDA, K., CASADESUS, G., PETERSEN, R. B., PERRY, G. & SMITH, M. A. 2004. Oxidative stress and redox-active iron in Alzheimer's disease. *Ann N Y Acad Sci*, 1012, 179-82.

- HSUCHOU, H., KASTIN, A. J., MISHRA, P. K. & PAN, W. 2012. C-reactive protein increases BBB permeability: implications for obesity and neuroinflammation. *Cell Physiol Biochem*, 30, 1109-19.
- KENKHUIS, B. 2022. Iron-immune interactions in Alzheimer's disease. Leiden University.
- KIM, J. & WESSLING-RESNICK, M. 2014. Iron and mechanisms of emotional behavior. *The Journal of nutritional biochemistry*, 25, 1101-1107.
- KOUTELEKOS, J. & HALIASOS, N. 2013. Depression and Thalassemia in children, adolescents and adults. *Health science journal*, 7, 239.
- KUBERA, M., OBUCHOWICZ, E., GOEHLER, L., BRZESZCZ, J. & MAES, M. 2011. In animal models, psychosocial stress-induced (neuro)inflammation, apoptosis and reduced neurogenesis are associated to the onset of depression. *Prog Neuropsychopharmacol Biol Psychiatry*, 35, 744-59.
- MAAROUFI, K., AMMARI, M., JELJELI, M., ROY, V., SAKLY, M. & ABDELMELEK, H. 2009. Impairment of emotional behavior and spatial learning in adult Wistar rats by ferrous sulfate. *Physiol Behav*, 96, 343-9.
- MAES, M. 2008. The cytokine hypothesis of depression: inflammation, oxidative & nitrosative stress (IO&NS) and leaky gut as new targets for adjunctive treatments in depression. *Neuro Endocrinol Lett*, 29, 287-91.
- MAES, M. & CARVALHO, A. F. 2018. The Compensatory Immune-Regulatory Reflex System (CIRS) in Depression and Bipolar Disorder. *Mol Neurobiol*, 55, 8885-8903.
- MAES, M., KUBERA, M. & KOTANSKA, M. 2022a. Aberrations in the Cross-Talks Among Redox, Nuclear Factor-κB, and Wnt/β-Catenin Pathway Signaling Underpin Myalgic Encephalomyelitis and Chronic Fatigue Syndrome. *Front Psychiatry*, 13, 822382.
- MAES, M., RACHAYON, M., JIRAKRAN, K., SODSAI, P., KLINCHANHOM, S., GAŁECKI, P., SUGHONDHABIROM, A. & BASTA-KAIM, A. 2022b. The immune profile of Major Dysmood Disorder: Proof of concept and mechanism using the precision nomothetic psychiatry approach. *Cells*, 11, 1183.
- MAES, M., THISAYAKORN, P., THIPAKORN, Y., TANTAVISUT, S., SIRIVICHAYAKUL, S. & VOJDANI, A. 2022c. Reactivity to neural tissue epitopes, aquaporin 4 and heat shock protein 60 is associated with activated immune-inflammatory pathways and the onset of delirium following hip fracture surgery. *medRxiv*.
- MAES, M., YIRMYIA, R., NORABERG, J., BRENE, S., HIBBELN, J., PERINI, G., KUBERA, M., BOB, P., LERER, B. & MAJ, M. 2009. The inflammatory & neurodegenerative (I&ND) hypothesis of depression: leads for future research and new drug developments in depression. *Metab Brain Dis*, 24, 27-53.
- MICHEL, M., FIEBICH, B. L., KUZIOR, H., MEIXENSBERGER, S., BERGER, B., MAIER, S., NICKEL, K., RUNGE, K., DENZEL, D., PANKRATZ, B., SCHIELE, M. A., DOMSCHKE, K., VAN ELST, L. T. & ENDRES, D. 2021. Increased GFAP concentrations in the cerebrospinal fluid of patients with unipolar depression. *Transl Psychiatry*, 11, 308.
- NANDAR, W., NEELY, E. B., UNGER, E. & CONNOR, J. R. 2013. A mutation in the HFE gene is associated with altered brain iron profiles and increased oxidative stress in mice. *Biochim Biophys Acta*, 1832, 729-41.
- NEGI, D., GRANAK, S., SHORTER, S., O'LEARY, V. B., REKTOR, I. & OVSEPIAN, S. V. 2023. Molecular biomarkers of neuronal injury in epilepsy shared with neurodegenerative diseases. *Neurotherapeutics*, 1-12.
- PAQUET-DURAND, F. & BICKER, G. 2007. Human model neurons in studies of brain cell damage and neural repair. *Current molecular medicine*, 7, 541-554.
- PARK, D.-W., PARK, S.-H. & HWANG, S.-K. 2019. Serial measurement of S100B and NSE in pediatric traumatic brain injury. *Child's Nervous System*, 35, 343-348.

- PLOG, B. A., DASHNAW, M. L., HITOMI, E., PENG, W., LIAO, Y., LOU, N., DEANE, R. & NEDERGAARD, M. 2015. Biomarkers of traumatic injury are transported from brain to blood via the glymphatic system. *Journal of Neuroscience*, 35, 518-526.
- POLITOU, M., KOMNINAKA, V., VALSAMI, S., KAPSIMALI, V., POULIAKIS, A., KOUTSOURI, T., PANAYIOTAKOPOULOS, G., KOTSIANIDIS, I. & VOSKARIDOU, E. 2020. The effect of transfusion on immune responses in thalassemia. *Blood Cells, Molecules, and Diseases*, 83, 102425.
- RAGURAM, A., BANSKOTA, S. & LIU, D. R. 2022. Therapeutic in vivo delivery of gene editing agents. *Cell*.
- ROUAULT, T. A. & COOPERMAN, S. Brain iron metabolism. Seminars in pediatric neurology, 2006. Elsevier, 142-148.
- RYBKA, J., KĘDZIORA-KORNATOWSKA, K., BANAŚ-LEŻAŃSKA, P., MAJSTEREK, I., CARVALHO, L. A., CATTANEO, A., ANACKER, C. & KĘDZIORA, J. 2013. Interplay between the pro-oxidant and antioxidant systems and proinflammatory cytokine levels, in relation to iron metabolism and the erythron in depression. *Free Radical Biology and Medicine*, 63, 187-194.
- SAHU, S., AGRAWAL, A., SHRIVASTAVA, J. & TONK, S. 2023. Psychiatric disorders and caregiver burden in children with transfusion dependent β-thalassaemia and their caregivers. *World J Clin Pediatr*, 12, 125-132.
- SCHIEPERS, O. J., WICHERS, M. C. & MAES, M. 2005. Cytokines and major depression. *Prog Neuropsychopharmacol Biol Psychiatry*, 29, 201-217.
- SCHIPPER, H. M. 2004. Brain iron deposition and the free radical-mitochondrial theory of ageing. *Ageing Res Rev*, **3**, 265-301.
- SCHNEIDER, S. A. & BHATIA, K. P. 2013. Excess iron harms the brain: the syndromes of neurodegeneration with brain iron accumulation (NBIA). *Journal of neural transmission*, 120, 695-703.
- SHAFIEE, A., NAZARI, S., JORJANI, S., BAHRAMINIA, E. & SADEGHI-KOUPAEI, M. 2014. Prevalence of depression in patients with β-thalassemia as assessed by the Beck's Depression Inventory. *Hemoglobin*, 38, 289-91.
- SHAH, F. H., IDREES, J., SHAH, S. T. A., KHAN, R., KHAN, A. T., SALMAN, S. & KHAN, A. A. 2020. Neurological deficits among beta-thalassemia patients and its possible therapeutic intervention: a comprehensive review. *Journal of the Dow University of Health Sciences (JDUHS)*, 14, 83-90.
- SHAH, F. T., SAYANI, F., TROMPETER, S., DRASAR, E. & PIGA, A. 2019. Challenges of blood transfusions in β-thalassemia. *Blood Reviews*, 37, 100588.
- SHAKI, F., SHAYESTE, Y., KARAMI, M., AKBARI, E., REZAEI, M. & ATAEE, R. 2017. The effect of epicatechin on oxidative stress and mitochondrial damage induced by homocycteine using isolated rat hippocampus mitochondria. *Research in Pharmaceutical Sciences*, 12, 119.
- SHALIGRAM, D., GIRIMAJI, S. & CHATURVEDI, S. 2007. Psychological problems and quality of life in children with thalassemia. *The Indian Journal of Pediatrics*, 74, 727-730.
- SLUZEWSKA, A., RYBAKOWSKI, J., BOSMANS, E., SOBIESKA, M., BERGHMANS, R., MAES, M. & WIKTOROWICZ, K. 1996. Indicators of immune activation in major depression. *Psychiatry Res*, 64, 161-167.
- SPANIER, S., KILIAN, H. M., MEYER, D. M. & SCHLAEPFER, T. E. 2019. Treatment resistance in major depression is correlated with increased plasma levels of neurofilament light protein reflecting axonal damage. *Med Hypotheses*, 127, 159-161.
- SPENCE, S. H., BARRETT, P. M. & TURNER, C. M. 2003. Psychometric properties of the Spence Children's Anxiety Scale with young adolescents. *J Anxiety Disord*, 17, 605-25.
- SRPOVA, B., UHER, T., HRNCIAROVA, T., BARRO, C., ANDELOVA, M., MICHALAK, Z., VANECKOVA, M., KRASENSKY, J., NOSKOVA, L. & HAVRDOVA, E. K. 2021. Serum

- neurofilament light chain reflects inflammation-driven neurodegeneration and predicts delayed brain volume loss in early stage of multiple sclerosis. *Mult Scler J*, 27, 52-60.
- STANKIEWICZ, J., PANTER, S. S., NEEMA, M., ARORA, A., BATT, C. E. & BAKSHI, R. 2007. Iron in chronic brain disorders: imaging and neurotherapeutic implications. *Neurotherapeutics*, 4, 371-386.
- STEINACKER, P., AL SHWEIKI, M. R., OECKL, P., GRAF, H., LUDOLPH, A. C., SCHÖNFELDT-LECUONA, C. & OTTO, M. 2021. Glial fibrillary acidic protein as blood biomarker for differential diagnosis and severity of major depressive disorder. *J Psychiat Res*, 144, 54-58.
- TORRES-PLATAS, S., NAGY, C., WAKID, M., TURECKI, G. & MECHAWAR, N. 2016. Glial fibrillary acidic protein is differentially expressed across cortical and subcortical regions in healthy brains and downregulated in the thalamus and caudate nucleus of depressed suicides. *Molecular psychiatry*, 21, 509-515.
- TREVISAN, C., VERONESE, N., BOLZETTA, F., DE RUI, M., CORRELL, C. U., ZAMBON, S., MUSACCHIO, E., SARTORI, L., PERISSINOTTO, E. & CREPALDI, G. 2016. Low hemoglobin levels and risk of developing depression in the elderly: Results from the prospective PRO. VA study. *The Journal of clinical psychiatry*, 77, 10882.
- TUOMAINEN, T. P., LOFT, S., NYYSSÖNEN, K., PUNNONEN, K., SALONEN, J. T. & POULSEN, H. E. 2007. Body iron is a contributor to oxidative damage of DNA. *Free Radic Res*, 41, 324-8.
- WANG, X. 2013. Brain Iron Deposition, Body Iron Overload and Cognitive Impairment.
- WANG, Y.-F. & PARPURA, V. 2016. Central role of maladapted astrocytic plasticity in ischemic brain edema formation. *Frontiers in cellular neuroscience*, 10, 129.
- WARD, R. J., ZUCCA, F. A., DUYN, J. H., CRICHTON, R. R. & ZECCA, L. 2014. The role of iron in brain ageing and neurodegenerative disorders. *The Lancet Neurology*, 13, 1045-1060.
- XIAN-HUI, D., WEI-JUAN, G., TIE-MEI, S., HONG-LIN, X., JIANG-TAO, B., JING-YI, Z. & XI-QING, C. 2015. Age-related changes of brain iron load changes in the frontal cortex in APPswe/PS1ΔE9 transgenic mouse model of Alzheimer's disease. *Journal of Trace Elements in Medicine and Biology*, 30, 118-123.
- YANG, Z. & WANG, K. K. 2015. Glial fibrillary acidic protein: from intermediate filament assembly and gliosis to neurobiomarker. *Trend Neurosci*, 38, 364-374.
- YATMARK, P., HUAIJANTUG, S., TEERAPAN, W., SVASTI, S., FUCHAROEN, S. & MORALES, N. P. 2019. MRI imaging and histopathological study of brain iron overload of β-thalassemic mice. *Magnetic Resonance Imaging*, 61, 267-272.
- YE, Q., TRIVEDI, M., ZHANG, Y., BÖHLKE, M., ALSULIMANI, H., CHANG, J., MAHER, T., DETH, R. & KIM, J. 2019. Brain iron loading impairs DNA methylation and alters GABAergic function in mice. *The FASEB Journal*, 33, 2460.
- YUAN, A. & NIXON, R. A. 2016. Specialized roles of neurofilament proteins in synapses: Relevance to neuropsychiatric disorders. *Brain Res Bull*, 126, 334-346.
- ZACHRISSON, O., REGLAND, B., JAHRESKOG, M., KRON, M. & GOTTFRIES, C. G. 2002. A rating scale for fibromyalgia and chronic fatigue syndrome (the FibroFatigue scale). *J Psychosom Res*, 52, 501-9.
- ZERR, I., SCHMITZ, M., KARCH, A., VILLAR-PIQUE, A., KANATA, E., GOLANSKA, E., DÍAZ-LUCENA, D., KARSANIDOU, A., HERMANN, P., KNIPPER, T., GOEBEL, S., VARGES, D., SKLAVIADIS, T., SIKORSKA, B., LIBERSKI, P. P., SANTANA, I., FERRER, I., ZETTERBERG, H., BLENNOW, K., CALERO, O., CALERO, M., LADOGANA, A., SáNCHEZ-VALLE, R., BALDEIRAS, I. & LLORENS, F. 2018. Cerebrospinal fluid neurofilament light levels in neurodegenerative dementia: Evaluation of diagnostic accuracy in the differential diagnosis of prion diseases. *Alzheimers Dement*, 14, 751-763.

ZHANG, P., CHEN, L., ZHAO, Q., DU, X., BI, M., LI, Y., JIAO, Q. & JIANG, H. 2020. Ferroptosis was more initial in cell death caused by iron overload and its underlying mechanism in Parkinson's disease. *Free Radical Biology and Medicine*, 152, 227-234.

Variables	НС	TDT patients	\mathbf{F}/χ^2	df	p	
	n=41	n=126				
Age (years)	9.76±2.05	10.02±2.35	0.40	1/165	0.528	
Sex (Female/Male)	19/22	56/70	0.05	1	0.832	
BMI (kg/m ²)	16.32±2.72	16.27±2.46	0.01	1/165	0.912	
Duration of disease (Years)	-	8.84±2.75	-	-	-	
Education (Years)	3.46±2.10	3.65±2.49	0.19	1/165	0.664	
Total Fibro-Fatigue score	2.02±1.151	23.50±6.941	387.53	1/165	< 0.001	
Total CDI score	3.63±2.447	20.81±8.36	167.77	1/165	< 0.001	
Total SCAS score	18.78±7.285	41.72±16.707	72.58	1/165	< 0.001	
PCV%	40.83±4.212	23.61±3.767	609.24	1/165	< 0.001	
Hb g/dl	13.808±1.363	8.242±1.217	42±1.217 609.58		< 0.001	
Ferritin ng/ml	74.683±29.175	3101.544±1998.010	93.70	1/165	< 0.001	
Iron μg/dl	117.408±20.551	203.006±64.723	69.19	1/165	< 0.001	

vn as mean (SD) or as ratios. F: results of analysis of variance, χ^2 : analysis of contingency tables. s index, CDI: Children's Depression Inventory, SCAS: The Spence Children's Anxiety Scale, PCV: packed cell volume, Hb: hemoglobin,

Variables	НС	TDT patients	F	df	p	
	n=41	n=126				
C-reactive protein mg/l	4.00±2.03	16.13±13.31	67.14	1/165	< 0.001	
Albumin g/dl	4.368±0.699	4.274±0.697	0.56	1/165	0.455	
Magnesium mM	1.269±0.295	1.058±0.253	19.65	1/165	< 0.001	
Calcium mM	2.484±0.218	2.218±0.221	45.16	1/165	< 0.001	
Copper mg/l	0.974±0.162	1.329±0.500	19.95	1/165	< 0.001	
Zinc mg/l	0.761±0.184	0.641±0.192	13.54	1/165	< 0.001	
IL-6 pg/ml	4.768±3.483	7.554±4.768	11.92	1/165	0.001	
IL-10 pg/ml	7.083±2.929	16.154±11.582	34.33	1/165	< 0.001	
Neuron-specific enolase ng/ml	0.787±0.563	1.291±1.442	7.33	1/165	0.008	
GFAP pg/ml	2.972±2.348	4.451±4.789	5.85	1/165	0.017	
NFL ng/ml	1.307±1.243	2.980±2.246	32.59	1/165	< 0.001	
Nestin ng/ml	34.126±17.051	42.167±30.873	1.44	1/165	0.231	
Comp_IRS (z score)	-0.983±0.629	0.320±0.884	76.40	1/165	< 0.001	
PC_neuronal (z score)	-0.399±0.696	0.130±1.051	9.08	1/165	0.003	

wn as mean (SD) or as ratios. F: results of analysis of variance; GFAP: Glial fibrillary acidic protein, NFL: neurofilament light chain, IL: PC: principal components; Comp: composite score, IRS: immune-inflammatory responses system.

	FF	CDI	SCAS	Comp_erythron	Comp_IO
C-Reactive protein	0.496***	0.446**	0.295***	-0.490***	0.536***
Albumin	-0.045	-0.075	-0.04	0.022	0.084
Magnesium	-0.307***	-0.262**	-0.12	0.319***	-0.225**
Calcium	-0.355***	-0.335**	-0.199**	0.411***	-0.385***
Copper	0.424***	0.332**	0.315***	-0.323***	0.497***
Zinc	-0.174*	-0.204**	-0.220**	0.231**	-0.078
Interleukin-6	0.194*	0.095	0.056	-0.225**	0.237**
Interleukin-10	0.346***	0.361***	0.159*	-0.389***	0.375***
Neuron-specific enolase	0.096	0.163*	-0.083	-0.221**	0.172*
Glial fibrillary acidic protein	0.203**	0.198**	-0.018	-0.192*	0.266***
Neurofilament light	0.322***	0.288***	0.333***	-0.361***	0.366***
Nestin	-0.002	-0.003	0.022	-0.055	0.144

.01, ***p<0.001

composite based on hematocrit and hemoglobin, Comp_IO: composite based on iron and ferritin reflecting iron overload, FF: Fibro-Fatigue score, Depression Inventory score, SCAS: The Spence Children's Anxiety Scale score.

Dependent Variables	Explanatory Variables	β	t	p	F model	df	p	\mathbb{R}^2
¹ 1 Fibro-Fatigue score	Model #1				24.21	5/161	< 0.001	0.429
	C-Reactive protein	0.307	4.70	< 0.001				
	Copper	0.270	4.16	< 0.001				
	Magnesium	-0.187	-2.99	0.003				
	Calcium	-0.169	-2.68	0.008				
	Neurofilament Light	0.140	2.21	0.029				
2. CDI-total score	Model #2				18.89	4/162	< 0.001	0.318
	C-Reactive protein	0.308	4.41	0.000				
	Interleukin-10	0.193	2.77	0.006				
	Calcium	-0.197	-2.90	0.004				
	Neurofilament Light	0.155	2.29	0.024				
3. SCAS total score	Model #3				12.24	4/162	< 0.001	0.232
	Neurofilament Light chain	0.214	2.93	0.004				
	C-Reactive Protein	0.164	2.25	0.026				
	Copper	0.223	3.00	0.003				
	Zinc	-0.191	-2.71	0.007				

Depression Inventory, SCAS: The Spence Children's Anxiety Scale

lent Variables	Explanatory Variables	β	t	p	F model	df	p	\mathbb{R}^2
ron-specific enolase	Model #1				17.39	1/165	< 0.001	0.095
	Interleukin-10	0.309	4.170	< 0.001				
1 filmillams a sidia mustain	Model #2				11.83	2/164	< 0.001	0.126
ıl fibrillary acidic protein	Interleukin-10	0.234	2.946	0.004				
	Interleukin-6	0.191	2.403	0.017				
mofilement Light shain	Model #3				16.24	2/164	< 0.001	0.165
rofilament Light chain	Hemoglobin	-0.297	-3.936	0.000				
	Copper	0.198	2.631	0.009				
tin	Model #4	1		1	9.71	2/164	<0.001	0.106
	Interleukin-6	0.247	3.266	0.001				
	Calcium	-0.165	-2.176	0.031				
_neuronal	Model #5				17.32	3/163	<0.001	0.242
	Interleukin-10	0.256	3.301	0.001				
	Interleukin-6	0.231	3.116	0.002				
	Ferritin	0.180	2.492	0.014				
np_inflammation	Model #6		•		30.46	2/164	< 0.001	0.271
	PCV%	-0.375	-4.54	< 0.001				
	Ferritin	0.202	2.45	0.015				

mponent; Comp: composite score.




Figure 1 Partial regression of the total Spence Children's Anxiety Scale (SCAS) on neurofilament light (NFL) levels, after adjusting for age and sex (p<0.001)

Figure 2. Partial regression of the glial fibrillary acidic protein (GFAP) on an index of immune-inflammatory response system (Comp_IRS) activation, after adjusting for age and sex (p< 0.001)




Figure 3. Partial regression of the neurofilament light (NFL) levels on hemoglobin levels, after adjusting for age and sex (p<0.001)




Figure 4. Partial regression of the immune-inflammatory response system (Comp_IRS) index on an erythron index based on hematocrit and hemoglobin measurements (Comp_erythron), after adjustment for age and sex (p<0.001)